630 related articles for article (PubMed ID: 24220253)
21. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
Grey AD; Chana MS; Popert R; Wolfe K; Liyanage SH; Acher PL
BJU Int; 2015 May; 115(5):728-35. PubMed ID: 25041307
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.
Somford DM; Hoeks CM; Hulsbergen-van de Kaa CA; Hambrock T; Fütterer JJ; Witjes JA; Bangma CH; Vergunst H; Smits GA; Oddens JR; van Oort IM; Barentsz JO;
Invest Radiol; 2013 Mar; 48(3):152-7. PubMed ID: 23328910
[TBL] [Abstract][Full Text] [Related]
23. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
[TBL] [Abstract][Full Text] [Related]
24. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.
Hamoen EHJ; de Rooij M; Witjes JA; Barentsz JO; Rovers MM
Eur Urol; 2015 Jun; 67(6):1112-1121. PubMed ID: 25466942
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric magnetic resonance imaging in the detection of prostate cancer.
Durmus T; Baur A; Hamm B
Rofo; 2014 Mar; 186(3):238-46. PubMed ID: 24452493
[TBL] [Abstract][Full Text] [Related]
26. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.
Felker ER; Lee-Felker SA; Feller J; Margolis DJ; Lu DS; Princenthal R; May S; Cohen M; Huang J; Yoshida J; Greenwood B; Kim HJ; Raman SS
Abdom Radiol (NY); 2016 May; 41(5):954-62. PubMed ID: 27118268
[TBL] [Abstract][Full Text] [Related]
27. Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
Bryk DJ; Llukani E; Huang WC; Lepor H
J Urol; 2015 Nov; 194(5):1234-40. PubMed ID: 26003206
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging-guided prostate biopsy: institutional analysis and systematic review.
Polanec SH; Helbich TH; Margreiter M; Klingler HC; Kubin K; Susani M; Pinker-Domenig K; Brader P
Rofo; 2014 May; 186(5):501-7. PubMed ID: 24497092
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
[TBL] [Abstract][Full Text] [Related]
30. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB.
Venderink W; Jenniskens SF; Michiel Sedelaar JP; Tamada T; Fütterer JJ
Korean J Radiol; 2018; 19(4):733-741. PubMed ID: 29962879
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
33. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
[TBL] [Abstract][Full Text] [Related]
34. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
[TBL] [Abstract][Full Text] [Related]
35. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
[TBL] [Abstract][Full Text] [Related]
36. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
37. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
[TBL] [Abstract][Full Text] [Related]
38. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
40. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
